Effective treatment of adolescents with aggression problems in clinical and non-clinical settings
ISRCTN | ISRCTN21681959 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN21681959 |
Secondary identifying numbers | III.04.1001 |
- Submission date
- 22/01/2010
- Registration date
- 06/04/2010
- Last edited
- 29/07/2010
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Floor Scheepers
Scientific
Scientific
Vluchtheuvellaan 6
Zetten
6670 AC
Netherlands
Phone | +31 (0)48 846 96 11 |
---|---|
f.scheepers@karakter.com |
Study information
Study design | Multicentre randomised treatment efficacy trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please contact Mr Tim Tiemissen [t.tiemissen@karakter.com] for more information |
Scientific title | Effective treatment of adolescents with aggression problems in clinical and non-clinical settings: a multicentre randomised treatment efficacy trial |
Study acronym | TOA |
Study objectives | Primary: To examine the comparative and combined effects of aggression replacement training (ART) and risperidone on aggressive behaviours among adolescents with aggression problems aged 12 - 21 years across clinical and non-clinical settings. Secondary: To examine how treatment response and non-responder profiles relate to contemporary dichotomised forms and correlates of aggressive behaviour (i.e. pro-active versus reactive, cognitive distortions), location where the treatment is offered. |
Ethics approval(s) | Ethical Board CMO Arnhem/Nijmegen, pending approval as of 22/01/2010 |
Health condition(s) or problem(s) studied | Aggression regulation problems |
Intervention | Patients are randomised to one of three treatment groups: 1. 30 sessions of aggression replacement training (ART) over a period of 14 weeks 2. Risperidone daily doses from 0.5 to 2 mg 3. Combination of both treatments Treatment: In the treatment phase, subjects will receive 14 weeks of each of the treatment conditions. After the treatment phase assessment of quantity, typology and severity of aggressive behaviour is conducted again, as well as the secondary outcome variables regarding the social background and clinical symptoms, social skills, aggressive thoughts and thinking styles. Follow up: After a period of three months and again at six months follow up measurements are conducted relating to our primary hypothesis. Medication is continued during these 6 months. Participants which have not responded to either or both of the treatment conditions are offered other treatments or are referred to the health care services which suit the problems and demand of the participants at that time. |
Intervention type | Other |
Primary outcome measure | A % decrease in severity and frequency of aggressive behaviour as observed on the MOAS, completed by at least two different informants at baseline and after the intervention period (including follow up measurements after three and six months). A decrease of 40% counts as a response to treatment, between 20 - 30% decrease as a partial response and a decrease below 20% as a non-response. |
Secondary outcome measures | 1. Impulsive-Premeditated Aggression Scale (IPAS) at pre-screening, and week 15 2. Clinical Global Impression 'Severity of Illness' (CGI-S) Scale at screening and week 15 3. REactive-PROactive Aggression Questionnaire (REPRO) (for parents, teachers, nurses or pedagogical workers) at screening and week 15 4. Instrument for Reactive and Proactive Aggression (IRPA) at screening and week 15 5. How I Think (HIT) questionnaire at screening and week 15 6. Social Support Questionnaire (SSQ) at screening and week 15 7. Socio-moral Reflection Objective Measure-Short Form (SROM-OSF) at screening and week 15 8. Inventory of callous-unemotional traits (ICU) at screening and week 15 9. Reactive-Proactive Aggression Questionnaire (RPQ) (for youths) at screening and week 15 |
Overall study start date | 01/07/2010 |
Completion date | 01/12/2011 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Other |
Sex | Both |
Target number of participants | 30 per treatment condition, total 120 |
Key inclusion criteria | 1. Full scale intelligence quotient (IQ) at least 80; total IQ (TIQ) less than 75, verbal IQ (VIQ) at least 80 2. Minimal score on Modified Overt Aggression Scale (MOAS) of 5 on both initial screenings 3. Age lies between 12 and 21 years, either sex 4. (Psychiatric) medication free at beginning of the screening procedure 5. Minimal motivation among participant and family 6. Reading level of Avi 6 or 7 |
Key exclusion criteria | 1. Previous ART or risperidone (6 months) 2. Psychotic condition 3. Severe depression 4. Severe substance dependency 5. Suicidal tendencies 6. Pregnancy or lactation 7. Major medical problems 8. Epilepsy 9. Cardiovascular diseases 10. Regular medication which strongly interacts with risperidone 11. Unable to sign informed consent |
Date of first enrolment | 01/07/2010 |
Date of final enrolment | 01/12/2011 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
Vluchtheuvellaan 6
Zetten
6670 AC
Netherlands
6670 AC
Netherlands
Sponsor information
Karakter - Child and Adolescent Psychiatry (Netherlands)
Hospital/treatment centre
Hospital/treatment centre
Horalaan 5
Ede
6717 LX
Netherlands
Website | http://www.karakter.com |
---|---|
https://ror.org/044jw3g30 |
Funders
Funder type
Hospital/treatment centre
Karakter - Child and Adolescent Psychiatry (Netherlands)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |